EMA Recommends Extension of Indications for Serplulimab By Ogkologos - April 22, 2026 182 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... January 8, 2024 FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC November 25, 2022 Reducing the Cancer Burden: Future Directions for NCI’s Cancer Control Research December 19, 2022 癌症可以在家族成员中被遗传吗? October 13, 2020 Load more HOT NEWS Mississippi Teen Uses Make-A-Wish Grant To Feed Homeless In His Community What the Budget 2021 means for research Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... Working to Close the Cancer Screening Gap Caused by COVID